SLC41A3 Exhibits as a Carcinoma Biomarker and Promoter in Liver Hepatocellular Carcinoma
Liver Hepatocellular Carcinoma (LIHC) is the fifth widely occurred carcinoma, which is thought to be the second primary contributor of carcinoma-associated death. There are almost 788,000 death tolls worldwide. Solute carrier family 41 member 3 (SLC41A3) is a member of solute carrier family 41, and...
Guardado en:
Autores principales: | , , , , , , , |
---|---|
Formato: | article |
Lenguaje: | EN |
Publicado: |
Hindawi Limited
2021
|
Materias: | |
Acceso en línea: | https://doaj.org/article/6a7818cd49c449fab1d2d834420a1ea2 |
Etiquetas: |
Agregar Etiqueta
Sin Etiquetas, Sea el primero en etiquetar este registro!
|
id |
oai:doaj.org-article:6a7818cd49c449fab1d2d834420a1ea2 |
---|---|
record_format |
dspace |
spelling |
oai:doaj.org-article:6a7818cd49c449fab1d2d834420a1ea22021-11-29T00:55:26ZSLC41A3 Exhibits as a Carcinoma Biomarker and Promoter in Liver Hepatocellular Carcinoma1748-671810.1155/2021/8556888https://doaj.org/article/6a7818cd49c449fab1d2d834420a1ea22021-01-01T00:00:00Zhttp://dx.doi.org/10.1155/2021/8556888https://doaj.org/toc/1748-6718Liver Hepatocellular Carcinoma (LIHC) is the fifth widely occurred carcinoma, which is thought to be the second primary contributor of carcinoma-associated death. There are almost 788,000 death tolls worldwide. Solute carrier family 41 member 3 (SLC41A3) is a member of solute carrier family 41, and it is the key point of numerous researches. Our research attempted to explore the links between SLC41A3 and LIHC through public databases. Higher expression of SLC41A3 displayed an intimate association with higher pathological stages and poorer prognosis. GO and KEGG analysis revealed the possible regulatory pathways of SLC41A3. Additionally, we carried out cell functional experiments to determine the expression of SLC41A3 in the cell lines of LIHC, as well as the effects of its silence on cell proliferation, migration, and invasion. Our data showed that SLC41A3 was greatly increased in the cell lines of LIHC. Moreover, silencing SLC41A3 impeded LIHC cell proliferation, migration, and invasion in vitro. Collectively, our study demonstrated that highly expressed SLC41A3 was a probable indication of LIHC occurrence, and SLC41A3 could be regarded as a prospective target in the treatment of LIHC.Qimeng ChangYayun XuJianfa WangHui JingLonghua RaoWeiguo TangZiping ZhangXubo WuHindawi LimitedarticleComputer applications to medicine. Medical informaticsR858-859.7ENComputational and Mathematical Methods in Medicine, Vol 2021 (2021) |
institution |
DOAJ |
collection |
DOAJ |
language |
EN |
topic |
Computer applications to medicine. Medical informatics R858-859.7 |
spellingShingle |
Computer applications to medicine. Medical informatics R858-859.7 Qimeng Chang Yayun Xu Jianfa Wang Hui Jing Longhua Rao Weiguo Tang Ziping Zhang Xubo Wu SLC41A3 Exhibits as a Carcinoma Biomarker and Promoter in Liver Hepatocellular Carcinoma |
description |
Liver Hepatocellular Carcinoma (LIHC) is the fifth widely occurred carcinoma, which is thought to be the second primary contributor of carcinoma-associated death. There are almost 788,000 death tolls worldwide. Solute carrier family 41 member 3 (SLC41A3) is a member of solute carrier family 41, and it is the key point of numerous researches. Our research attempted to explore the links between SLC41A3 and LIHC through public databases. Higher expression of SLC41A3 displayed an intimate association with higher pathological stages and poorer prognosis. GO and KEGG analysis revealed the possible regulatory pathways of SLC41A3. Additionally, we carried out cell functional experiments to determine the expression of SLC41A3 in the cell lines of LIHC, as well as the effects of its silence on cell proliferation, migration, and invasion. Our data showed that SLC41A3 was greatly increased in the cell lines of LIHC. Moreover, silencing SLC41A3 impeded LIHC cell proliferation, migration, and invasion in vitro. Collectively, our study demonstrated that highly expressed SLC41A3 was a probable indication of LIHC occurrence, and SLC41A3 could be regarded as a prospective target in the treatment of LIHC. |
format |
article |
author |
Qimeng Chang Yayun Xu Jianfa Wang Hui Jing Longhua Rao Weiguo Tang Ziping Zhang Xubo Wu |
author_facet |
Qimeng Chang Yayun Xu Jianfa Wang Hui Jing Longhua Rao Weiguo Tang Ziping Zhang Xubo Wu |
author_sort |
Qimeng Chang |
title |
SLC41A3 Exhibits as a Carcinoma Biomarker and Promoter in Liver Hepatocellular Carcinoma |
title_short |
SLC41A3 Exhibits as a Carcinoma Biomarker and Promoter in Liver Hepatocellular Carcinoma |
title_full |
SLC41A3 Exhibits as a Carcinoma Biomarker and Promoter in Liver Hepatocellular Carcinoma |
title_fullStr |
SLC41A3 Exhibits as a Carcinoma Biomarker and Promoter in Liver Hepatocellular Carcinoma |
title_full_unstemmed |
SLC41A3 Exhibits as a Carcinoma Biomarker and Promoter in Liver Hepatocellular Carcinoma |
title_sort |
slc41a3 exhibits as a carcinoma biomarker and promoter in liver hepatocellular carcinoma |
publisher |
Hindawi Limited |
publishDate |
2021 |
url |
https://doaj.org/article/6a7818cd49c449fab1d2d834420a1ea2 |
work_keys_str_mv |
AT qimengchang slc41a3exhibitsasacarcinomabiomarkerandpromoterinliverhepatocellularcarcinoma AT yayunxu slc41a3exhibitsasacarcinomabiomarkerandpromoterinliverhepatocellularcarcinoma AT jianfawang slc41a3exhibitsasacarcinomabiomarkerandpromoterinliverhepatocellularcarcinoma AT huijing slc41a3exhibitsasacarcinomabiomarkerandpromoterinliverhepatocellularcarcinoma AT longhuarao slc41a3exhibitsasacarcinomabiomarkerandpromoterinliverhepatocellularcarcinoma AT weiguotang slc41a3exhibitsasacarcinomabiomarkerandpromoterinliverhepatocellularcarcinoma AT zipingzhang slc41a3exhibitsasacarcinomabiomarkerandpromoterinliverhepatocellularcarcinoma AT xubowu slc41a3exhibitsasacarcinomabiomarkerandpromoterinliverhepatocellularcarcinoma |
_version_ |
1718407773735092224 |